Additional file 2 of Construction and investigation of a circRNA-associated ceRNA regulatory network in Tetralogy of Fallot

Additional file 2. Table 2 ceRNA regulatory modules

Additional file 1 of Transforming growth factor-induced gene TGFBI is correlated with the prognosis and immune infiltrations of breast cancer

Additional file 1

YSU-an EEG dataset for studying asynchronous SSVEP-BCI

Update later.</p

Additional file 6 of Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT

Supplementary Material 6 Table S1. Search Term

sj-docx-1-jht-10.1177_10963480221109551 – Supplemental material for Greenwashing in workplace: The influencing mechanism of psychological contract fulfillment and the moderating role of ethical work climate

Supplemental material, sj-docx-1-jht-10.1177_10963480221109551 for Greenwashing in workplace: The influencing mechanism of psychological contract fulfillment and the moderating role of ethical work climate by Hairong Zhao, Yan Xu and Xinrui Wang in Journal of Hospitality & Tourism Research</p

Additional file 1 of Construction and investigation of a circRNA-associated ceRNA regulatory network in Tetralogy of Fallot

Additional file 1. Table 1 Differentially expressed circRNAs between the TOF group and the healthy control group

Additional file 2 of Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT

Supplementary Material 2 Figure S2. Summary of Risk Assessment Using the Cochrane Collaboration’s Tool For Assessing the Risk of Bia

Additional file 1 of Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT

Supplementary Material 1 Figure S1. PRISMA Flow Diagra

Additional file 1 of Prognostic analysis of E2F transcription factors E2F1 and E2F3 in four independent pediatric neuroblastoma cohorts

Additional file 1: Supplementary Figure 1. (a) The detailed four independent datasets used in this study. (b) Different event free survival or overall survival of pediatric neuroblastoma patients in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets. Supplementary Figure 2. Additively prognostic effects of E2F1 with MYCN amplification or age of diagnosis in neuroblastoma. (a) Different event free survival in each sub-group of pediatric neuroblastoma based on the expression levels of E2F1 and MYCN amplification in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets. (b) Different event free survival in each sub-group of pediatric neuroblastoma based on the expression levels of E2F1 and age of diagnosis was determined. Supplementary Figure 3. Additively prognostic effects of E2F3 with MYCN amplification or age of diagnosis in neuroblastoma. (a) Different event free survival in each sub-group of pediatric neuroblastoma based on the expression levels of E2F3 and MYCN amplification in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets. (b) Different event free survival in each sub-group of pediatric neuroblastoma based on the expression levels of E2F3 and age of diagnosis was determined

Additional file 1 of Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies

Additional file 1 Table S1. Search terms. Table S2. Summary of risk of bias assessment using ROBINS-I tool. Fig. S1. Eggers’s test of studies examining the association between opioids exposure and the risk of congenital malformations. Fig. S2. Forest plot of association between opioid exposure and major congenital malformation. Fig. S3. Forest plot of association between opioid exposure and central nervous system malformation. Fig. S4. Forest plot of association between opioid exposure and limb malformation. Fig. S5. Forest plot of assoxiation between opioid exposure and cardiovascular malformation. Fig. S6. Forest plot of association between opioid exposure and gastrointestinal malformation. Fig. S7. Forest plot of association between opioid exposure and ear, face, and neck malformation. Fig. S8. Forest plot of association between opioid exposure and respiratory malformation. Fig. S9. Forest plot of association between opioid exposure and musculoskeletal malformation. Fig. S10. Forest plot of association between opioid exposure and urogenital malformation. Fig. S11. Forest plot of association between opioid exposure and orofacial malformation. Fig. S12. Forest plot of association between opioid exposure and neural tube defects. Fig. S13. Forest plot of association between opioid exposure and gastroschisis. Fig. S14. Forest plot of association between opioid exposure and clubfoot. Fig. S15. Meta-regression according to the year of publication. Fig. S16. Forest plot of subgroup analysis of exposed period. Fig. S17. Forest plot of subgroup analysis of indication. Fig. S18: Forest plot of subgroup analysis of adjusted for confounders. Fig. S19. Forest plot of subgroup analysis of risk of bias assessment